Tislelizumab Combined with Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DRUG: Tislelizumab, Carboplatin /Cisplatin, Etoposide
Progression Free Survival (PFS), To evaluate the efficacy of Tislelizumab + cisplatin or carboplatin + etoposide and radiotherapy in the intent to treat (ITT) Analysis Set as measured by investigator assessed progression free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Baseline until PD or death, whichever occurs first or up to approximately 23 months
Objective Response Rate (ORR), To evaluate the efficacy of Tislelizumab + cisplatin or carboplatin + etoposide +radiotherapy in the ITT Analysis Set as measured by investigator assessed overall response rate (ORR), according to RECIST v1.1, Baseline until partial response (PR) or complete response (CR), whichever occurs or up to approximately 23 months|Duration Of Response (DOR), To evaluate the efficacy of Tislelizumab + cisplatin or carboplatin + etoposide+ radiotherapy in the ITT Analysis Set as measured by investigator assessed duration of response (DOR) according to RECIST v1.1, Baseline until partial response (PR) or complete response (CR), whichever occurs first, or up to approximately 23 months|Disease Control Rate (DCR), To evaluate the efficacy of Tislelizumab + cisplatin or carboplatin + etoposide + radiotherapy in the ITT Analysis Set as measured by investigator assessed disease control rate (DCR) according to RECIST v1.1, up to approximately 23 months|6-moth/1-year Progression Free Survival (PFS) Rate, The PFS rate will be defined as the proportion of participants free from PFS events at 6 month and 1st year after the first dose., up to approximately 23 months|1-year Overall Survival (OS) rate, The OS rate will be defined as the proportion of participants free from OS events at 1st year after the first dose., up to approximately 23 months|Number Of Participants Experiencing Treatment-Emergent Adverse Events, Incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, up to approximately 23 months
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer